NextGen Sciences Strengthens Protein Biomarker Team with Two Key Appointments
NextGen Group plc has announced the expansion of its protein biomarker team with the appointment of Dr. Ruth VanBogelen as Director of biomarkers and proteomics and Dr. M. Walid Qoronfleh as Vice President of business development. These appointments are part of the Group's strategy to focus resources on growing the biomarker service business to meet the needs of its customers.
Dr. VanBogelen joins NextGen Sciences from Pfizer, Inc., where she was Director of Proteomics for Research and Development. She has thirty years of experience using proteomics technologies to generate and test hypotheses for pre-clinical and clinical programs in both industry and academia. Prior to Pfizer (and Warner-Lambert) she lead research into microbial proteomics at the University of Michigan Medical Center. Dr. VanBogelen has published over 30 peer-reviewed scientific papers and has authored numerous review articles and book chapters on proteomics. She currently serves on the Editorial Board for the journals Proteomics, Proteomics Clinical Applications and the Journal of Proteomics and Bioinformatics.
Dr. Walid Qoronfleh joins NextGen Sciences from the successful Q3 Consulting Group where he was a founder and Managing Director. With over 20 years of commercial experience, Walid has held various senior management and executive positions at AntexPharma, Pierce Biotechnology (now part of ThermoFisher) and CTA Corp/University of Michigan-Ann Arbor. Walid's previous scientific, R&D and technology appointments include SmithKline Beecham (now GlaxoSmithKline), Sterling-Winthrop Pharmaceuticals (now part of Sanofi-Aventis) and the National Cancer Institute. Walid received an MBA from Penn State University as well as a Marketing certificate from the University of Wisconsin-Madison.
Other news from the department people
